Arabella Young, PhD

Languages spoken: English

Academic Information

Departments: Pathology - Assistant Professor

Divisions: Microbiology and Immunology

Academic Office Information

arabella.young@hci.utah.edu

(801) 646-4222

Huntsman Cancer Institute Research North

2000 Circle of Hope, Room:
Salt Lake City, UT 84112

Labs

Research Interests

  • Immune-Related Adverse Events
  • Immune Checkpoint Inhibitors
  • Autoimmunity
  • Tumor Microenvironment
  • Cancer Immunotherapy
  • Novel Immune Targets for Cancer Therapy

Education History

Fellowship University of California San Francisco
Immune toxicity 		Postdoctoral Research Fellow
Doctoral Training The University of Queensland
Immunology 		Ph.D.
Undergraduate University of Tasmania
Plant Science 		BBiotech(Hons)

Selected Publications

  1. VanDyke D, Iglesias M, Tomala J, Young A, Smith J, Perry JA, Gebara E, Cross AR, Cheung LS, Dykema AG, Orcutt-Jahns BT, Henclov T, Golias J, Balolong J, Tomasovic LM, Funda D, Meyer AS, Pardoll DM, Hester J, Issa F, Hunter CA, Anderson MS, Bluestone JA, Raimondi G, Spangler JB (2022). Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection. Cell Rep, 41(3), 111478.
  2. Perdigoto AL, Deng S, Du KC, Kuchroo M, Burkhardt DB, Tong A, Israel G, Robert ME, Weisberg SP, Kirkiles-Smith N, Stamatouli AM, Kluger HM, Quandt Z, Young A, Yang ML, Mamula MJ, Pober JS, Anderson MS, Krishnaswamy S, Herold KC (2022). Immune cells and their inflammatory mediators modify β cells and cause checkpoint inhibitor-induced diabetes. JCI Insight, 7(17).
  3. Kang JH, Bluestone JA, Young A (2021). Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines. Trends Immunol, 42(4), 293-311.
  4. Young A, Bluestone JA (2021). At the Heart of Immune Checkpoint Inhibitor-Induced Immune Toxicity. Cancer Discov, 11(3), 537-539.
  5. Quandt Z, Young A, Perdigoto AL, Herold KC, Anderson MS (2020). Autoimmune Endocrinopathies: An Emerging Complication of Immune Checkpoint Inhibitors. Annu Rev Med, 72, 313-330.
  6. Lee JC, Mehdizadeh S, Smith J, Young A, Mufazalov IA, Mowery CT, Daud A, Bluestone JA (2019). Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis. Sci Immunol, 5(52).
  7. Quandt Z, Coupe C, Anderson M, Uihlein A, Young A (2020). Breaking β Cell Tolerance After 100 Years of Life: Intratumoral Immunotherapy-Induced Diabetes Mellitus. J Endocr Soc, 4(10), bvaa114.
  8. Ngiow SF, Young A (2020). Re-education of the Tumor Microenvironment With Targeted Therapies and Immunotherapies. Front Immunol, 11, 1633.
  9. Quandt Z, Young A, Anderson M (2020). Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes. Clin Exp Immunol, 200(2), 131-140.
  10. Sutton LP, Jeffreys SA, Phillips JL, Taberlay PC, Holloway AF, Ambrose M, Joo JE, Young A, Berry R, Skala M, Brettingham-Moore KH (2019). DNA methylation changes following DNA damage in prostate cancer cells. Epigenetics, 14(10), 989-1002.
  11. Young A, Quandt Z, Bluestone JA (2018). The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy. Cancer Immunol Res, 6(12), 1445-1452.
  12. Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, Gettinger S, Sznol M, Young A, Rushakoff R, Lee J, Bluestone JA, Anderson M, Herold KC (2018). Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors. Diabetes, 67(8), 1471-1480.
  13. Wang D, Quiros J, Mahuron K, Pai CC, Ranzani V, Young A, Silveria S, Harwin T, Abnousian A, Pagani M, Rosenblum MD, Van Gool F, Fong L, Bluestone JA, DuPage M (2018). Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity. Cell Rep, 23(11), 3262-3274.
  14. Young A, Ngiow SF, Gao Y, Patch AM, Barkauskas DS, Messaoudene M, Lin G, Coudert JD, Stannard KA, Zitvogel L, Degli-Esposti MA, Vivier E, Waddell N, Linden J, Huntington ND, Souza-Fonseca-Guimaraes F, Smyth MJ (2017). A2AR Adenosine Signaling Suppresses Natural Killer Cell Maturation in the Tumor Microenvironment. Cancer Res, 78(4), 1003-1016.
  15. Vijayan D, Young A, Teng MWL, Smyth MJ (2017). Targeting immunosuppressive adenosine in cancer. Nat Rev Cancer, 17(12), 709-724.
  16. Young A, Ngiow SF, Madore J, Reinhardt J, Landsberg J, Chitsazan A, Rautela J, Bald T, Barkauskas DS, Ahern E, Huntington ND, Schadendorf D, Long GV, Boyle GM, Hlzel M, Scolyer RA, Smyth MJ (2017). Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis. Cancer Res, 77(17), 4684-4696.
  17. Reinhardt J, Landsberg J, Schmid-Burgk JL, Ramis BB, Bald T, Glodde N, Lopez-Ramos D, Young A, Ngiow SF, Nettersheim D, Schorle H, Quast T, Kolanus W, Schadendorf D, Long GV, Madore J, Scolyer RA, Ribas A, Smyth MJ, Tumeh PC, Tting T, Hlzel M (2017). MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy. Cancer Res, 77(17), 4697-4709.
  18. Gao Y, Souza-Fonseca-Guimaraes F, Bald T, Ng SS, Young A, Ngiow SF, Rautela J, Straube J, Waddell N, Blake SJ, Yan J, Bartholin L, Lee JS, Vivier E, Takeda K, Messaoudene M, Zitvogel L, Teng MWL, Belz GT, Engwerda CR, Huntington ND, Nakamura K, Hlzel M, Smyth MJ (2017). Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells. Nat Immunol, 18(9), 1004-1015.
  19. Casciello F, Al-Ejeh F, Kelly G, Brennan DJ, Ngiow SF, Young A, Stoll T, Windloch K, Hill MM, Smyth MJ, Gannon F, Lee JS (2017). G9a drives hypoxia-mediated gene repression for breast cancer cell survival and tumorigenesis. Proc Natl Acad Sci U S A, 114(27), 7077-7082.
  20. Liu J, Blake SJ, Yong MC, Harjunp H, Ngiow SF, Takeda K, Young A, ODonnell JS, Allen S, Smyth MJ, Teng MW (2016). Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease. Cancer Discov, 6(12), 1382-1399.
  21. Ngiow SF, Young A, Blake SJ, Hill GR, Yagita H, Teng MW, Korman AJ, Smyth MJ (2016). Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell-Rich Tumor. Cancer Res, 76(21), 6266-6277.
  22. Young A, Ngiow SF, Barkauskas DS, Sult E, Hay C, Blake SJ, Huang Q, Liu J, Takeda K, Teng MWL, Sachsenmeier K, Smyth MJ (2016). Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses. Cancer Cell, 30(3), 391-403.
  23. Mittal D, Sinha D, Barkauskas D, Young A, Kalimutho M, Stannard K, Caramia F, Haibe-Kains B, Stagg J, Khanna KK, Loi S, Smyth MJ (2016). Adenosine 2B Receptor Expression on Cancer Cells Promotes Metastasis. Cancer Res, 76(15), 4372-82.
  24. Qadi AA, Taberlay PC, Phillips JL, Young A, West AC, Brettingham-Moore KH, Dickinson JL, Holloway AF (2015). The Leukemia Inhibitory Factor Receptor Gene Is a Direct Target of RUNX1. J Cell Biochem, 117(1), 49-58.
  25. Ngiow SF, Young A, Jacquelot N, Yamazaki T, Enot D, Zitvogel L, Smyth MJ (2015). A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1. Cancer Res, 75(18), 3800-11.
  26. Souza-Fonseca-Guimaraes F, Young A, Smyth MJ (2015). IFN type III: in vivo NK cell response. Oncotarget, 6(24), 19960-1.
  27. Souza-Fonseca-Guimaraes F, Young A, Mittal D, Martinet L, Bruedigam C, Takeda K, Andoniou CE, Degli-Esposti MA, Hill GR, Smyth MJ (2015). NK cells require IL-28R for optimal in vivo activity. Proc Natl Acad Sci U S A, 112(18), E2376-84.
  28. Young A, Mittal D, Stannard K, Yong M, Teng MW, Allard B, Stagg J, Smyth MJ (2014). Co-blockade of immune checkpoints and adenosine A2A receptor suppresses metastasis. Oncoimmunology, 3(10), e958952.
  29. Young A, Berry R, Holloway AF, Blackburn NB, Dickinson JL, Skala M, Phillips JL, Brettingham-Moore KH (2014). RNA-seq profiling of a radiation resistant and radiation sensitive prostate cancer cell line highlights opposing regulation of DNA repair and targets for radiosensitization. BMC Cancer, 14, 808.
  30. Young A, Mittal D, Stagg J, Smyth MJ (2014). Targeting cancer-derived adenosine: new therapeutic approaches. Cancer Discov, 4(8), 879-88.
  31. Mittal D, Young A, Stannard K, Yong M, Teng MW, Allard B, Stagg J, Smyth MJ (2014). Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor. Cancer Res, 74(14), 3652-8.
  32. Poke FS, Upcher WR, Sprod OR, Young A, Brettingham-Moore KH, Holloway AF (2012). Depletion of c-Rel from cytokine gene promoters is required for chromatin reassembly and termination of gene responses to T cell activation. PLoS One, 7(7), e41734.